SIM
KRTX

Sandia Investment Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Sandia Investment Management’s Portfolio KRTX Stock Details KRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-2,000
Closed -$363K – 305
2023
Q1 		$363K Buy
+2,000
New +$383K 0.07% 111

Other funds holding KRTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Sandia Investment Management's KRTX Position: Q2 2023 in Review

Sandia Investment Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q2 2023, closing a stake of 2,000 shares — an estimated $363K sold.

Sandia Investment Management first reported a position in KRTX in Q1 2023 and held it in 1 quarter. The position peaked at $363K in Q1 2023. 289 funds tracked by Wall St. Rank hold KRTX as of Q2 2023.

  • Sandia Investment Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
  • Sandia Investment Management sold 2,000 Karuna Therapeutics, Inc. Common Stock shares in Q2 2023, an estimated $363K.
  • Sandia Investment Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q1 2023 and held it in 1 quarter.
  • Sandia Investment Management's Karuna Therapeutics, Inc. Common Stock position peaked at $363K in Q1 2023.
  • 289 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q2 2023.

Based on Sandia Investment Management's 13F filing for Q2 2023, filed 14 Aug 2023.